Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer
| Autor: | Abenaa M. Brewster, Francisco J. Esteva, Sandra X. Franco, K. Koch, William V. Williams, M. Ridderheim, Alejandra T. Perez, A. Florance, M. K. Hagan, Stuart J. Turner |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Lapatinib medicine.disease Metastatic breast cancer chemistry.chemical_compound Paclitaxel chemistry Tolerability Trastuzumab Internal medicine Concomitant Cohort Medicine Lapatinib/trastuzumab skin and connective tissue diseases business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:1046-1046 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 1046 Background: Although concomitant trastuzumab and paclitaxel is an established treatment for metastatic breast cancer (MBC), 30% to 40% of HER2-positive patients show no response to this combination. Lapatinib, with a differing mechanism of action, may increase efficacy when given concurrently with trastuzumab and paclitaxel. Methods: This is an open-label phase I study with the primary objective of assessing the safety and tolerability of lapatinib when administered with paclitaxel and trastuzumab. The secondary objective was to determine the efficacy of lapatinib via overall response rate (ORR), duration of response and time to response. Patients were enrolled sequentially into 1 of 3 cohorts. Cohort 1 received lapatinib (1,000 mg/d), paclitaxel (80 mg/m2 weekly for 3 weeks of a 4-week cycle), and the standard weekly dose of trastuzumab (2 mg/kg). Cohort 2 received lapatinib (1,000 mg/d), paclitaxel (70 mg/m2), and trastuzumab. Cohort 3 received lapatinib (750 mg/d), paclitaxel (80 mg/m2), and trast... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|